secwatch / observer
8-K filed June 7, 2023, 7:59 PM ET ticker KNSA CIK 0001730430
other material confidence high sentiment neutral materiality 0.15

Kiniksa annual meeting elects three directors, ratifies auditor, approves say-on-pay

Kiniksa Pharmaceuticals International, plc

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

Kiniksa Pharmaceuticals International, plc shareholders approved Advisory approval of the compensation of named executive officers as disclosed in the proxy statement at the 2023-06-06 meeting.

Proposal
say on pay
Outcome
passed
Meeting
2023-06-06
Exact text from the filing
Proposal 3 – The approval, on a non-binding, advisory basis, of the compensation of our named executive officers as disclosed in the Company’s proxy statement for the Annual Meeting pursuant to the applicable compensation disclosure rules of the Securities and Exchange Commission, including the compensation tables and narrative discussion. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 40,423,385 1,270,222 380,052 3,132,968
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

Kiniksa Pharmaceuticals International, plc shareholders approved Election of Stephen R. Biggar, G. Bradley Cole and Barry D. Quart as Class II Directors to serve until the 2026 Annual Meeting at the 2023-06-06 meeting.

Proposal
director election
Outcome
passed
Meeting
2023-06-06
Exact text from the filing
Proposal 1 – The election of Stephen R. Biggar, G. Bradley Cole and Barry D. Quart as Class II Directors to serve until the 2026 Annual Meeting of Shareholders and until their respective successors have been duly elected and qualified. Nominee Votes FOR Votes WITHHELD Broker Non-Votes Stephen R. Biggar 30,959,772 11,113,887 3,132,968 G. Bradley Cole 40,974,400 1,099,259 3,132,968 Barry D. Quart 40,953,831 1,119,828 3,132,968
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

Kiniksa Pharmaceuticals International, plc shareholders approved Appointment of PricewaterhouseCoopers LLP as auditor and ratification of their appointment for fiscal year 2023 at the 2023-06-06 meeting.

Proposal
auditor ratification
Outcome
passed
Meeting
2023-06-06
Exact text from the filing
Proposal 2 – The (a) appointment of PricewaterhouseCoopers LLP as the Company’s auditor until the close of the Company’s next Annual Meeting of Shareholders, (b) delegation to the Company’s Board of Directors, through the Audit Committee of the Board of Directors, of the authority to set the auditor’s remuneration for such period, and (c) ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 44,804,941 23,637 378,049 0
View on SEC.gov

Browse all shareholder votes →

Kiniksa Pharmaceuticals International, plc filing history →

Source: SEC EDGAR
accession 0001104659-23-068966
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.